Expertise in
5
conditions

Dr. Matthew J. Zirwas

Dermatology
2359 East Main Street, 
Bexley, OH 
Accepting New Patients
Referral may be required
Expertise in
5
conditions
2359 East Main Street, 
Bexley, OH 

Overview

Matthew Zirwas is a Dermatologist practicing medicine in Bexley, Ohio.

Dr. Zirwas is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Atopic Dermatitis, Contact Dermatitis, Plaque Psoriasis, and Psoriasis.

Dr. Zirwas is board certified in American Board Of Dermatology. He is actively involved in clinical research, co-authoring 138 peer reviewed articles and participating in 12 clinical trials. Dr. Zirwas is currently accepting new patients.

Graduate Institution

University Of Pittsburgh School Of Medicine, 2000

Residency

Upmc Presbyterian, Dermatology, 2004

Specialties

Dermatology

Licenses

Dermatology in OH

Board Certifications

American Board Of Dermatology

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Health
  • HMO
  • PPO
Medical Mutual
  • HMO
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Dermatologists of Southwest Ohio, Inc.
2359 East Main Street, Bexley, OH 43209
Other Locations
Dermatologists of Southwest Ohio, Inc.
5300 Far Hills Avenue, Dayton, OH 45429

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Randomized, Double-Blind, Vehicle-Controlled, Sample Size Adaptive Design Study to Evaluate the Safety and Efficacy of Topically Applied EB01 Cream in Healthy Adult Volunteers and Adult Subjects with Moderate to Severe Chronic Allergic Contact Dermatitis
A Randomized, Double-Blind, Vehicle-Controlled, Sample Size Adaptive Design Study to Evaluate the Safety and Efficacy of Topically Applied EB01 Cream in Healthy Adult Volunteers and Adult Subjects with Moderate to Severe Chronic Allergic Contact Dermatitis
Enrollment Status: Completed
Publish Date: November 14, 2024
Intervention Type: Drug
Study Drug: EB01 Cream
Study Phase: Phase 2
A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
Enrollment Status: Terminated
Publish Date: September 18, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-controlled, Phase 2B Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled, Phase 2B Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy
Enrollment Status: Completed
Publish Date: May 09, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
Enrollment Status: Terminated
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 09, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: July 28, 2020
Intervention Type: Drug
Study Phase: Phase 4
View 7 Less Clinical Trials

123 Total Publications

What Dermatology Residents Need to Know About Joining Group Practices.
What Dermatology Residents Need to Know About Joining Group Practices.
Journal: Cutis
Published: March 16, 2026
Similar Doctors
Expertise in
28
conditions
Dr. Benjamin Kaffenberger
Dermatology
Expertise in
28
conditions
Dr. Benjamin Kaffenberger
Dermatology
1328 Dublin Rd, 
Columbus, OH 
 (6.9 miles away)
614-293-1707
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Benjamin Kaffenberger is a Dermatologist practicing medicine in Columbus, Ohio. Dr. Kaffenberger is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Pyoderma Gangrenosum, Cellulitis, DRESS Syndrome, Erythema Multiforme, and Tissue Biopsy.

Expertise in
4
conditions
Dr. Susan Nedorost
Dermatology
Expertise in
4
conditions
Dr. Susan Nedorost
Dermatology

Dermatologists Of Southwest Ohio, Inc.

2359 East Main Street, 
Bexley, OH 
 (0.3 miles away)
614-664-5925
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Susan Nedorost is a Dermatologist practicing medicine in Bexley, Ohio. Dr. Nedorost is highly rated in 4 conditions, according to our data. Her clinical expertise encompasses Stasis Dermatitis and Ulcers, Contact Dermatitis, Pompholyx Eczema, and Atopic Dermatitis. Dr. Nedorost is board certified in American Board Of Dermatology. Dr. Nedorost is currently accepting new patients.

Expertise in
44
conditions
Dr. Timothy Storer
Dermatology
Expertise in
44
conditions
Dr. Timothy Storer
Dermatology
3595 Olentangy River Rd, 
Columbus, OH 
 (7.4 miles away)
419-947-1707
Languages Spoken:
English
See accepted insurances

Timothy Storer is a Dermatologist practicing medicine in Columbus, Ohio. Dr. Storer is highly rated in 44 conditions, according to our data. His clinical expertise encompasses Actinic Keratosis, Warts, Seborrheic Keratosis, and Sebaceous Adenoma.

Frequently Asked Questions about Dr. Matthew J. Zirwas

How do I make an appointment with Dr. Matthew J. Zirwas?

You can book an appointment with Dr. Matthew J. Zirwas by calling their office at 614-664-5925. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Matthew J. Zirwas a top-rated expert for Atopic Dermatitis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Matthew J. Zirwas is classified as an Distinguished expert for Atopic Dermatitis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Matthew J. Zirwas specialize in?

While Dr. Matthew J. Zirwas is a Dermatology, they have specific expertise in Atopic Dermatitis, Contact Dermatitis, and Plaque Psoriasis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Dermatology.

Does Dr. Matthew J. Zirwas participate in research or clinical trials?

Yes. Dr. Matthew J. Zirwas has published 123 articles and abstracts on conditions like Atopic Dermatitis. You can view a list of Dr. Matthew J. Zirwas's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Matthew J. Zirwas accept my insurance?

Dr. Matthew J. Zirwas accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 614-664-5925 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Zirwas's expertise for a condition
ConditionClose
    View All 24 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile